ALLMedicine™ Clostridium Difficile Infection Center

Feb 12th, 2021 - Background: Proton pump inhibitor (PPI) exposure is associated with Clostridium difficile infection (CDI). The impact of the route of administration is unknown. Patients in the Multiparameter Intelligent Monitoring in Intensive Care II database (M...

Feb 3rd, 2021 - Proton pump inhibitor (PPI) use is extremely common. PPIs have been suggested to affect the gut microbiome, and increase risks of Clostridium difficile infection and small intestinal bacterial overgrowth (SIBO). However, existing data are based on...

Dec 31st, 2020 - Empiric antimicrobial therapy for healthcare-acquired infections often includes vancomycin plus an antipseudomonal beta-lactam (AP-BL). These agents vary in risk for adverse events, including acute kidney injury (AKI) and Clostridium difficile inf...

Dec 30th, 2020 - Infectious diseases are a threat to elderly individuals, whose immune systems weaken with age. Among the various infectious diseases, Clostridium difficile infection is associated with a high rate of mortality in elderly individuals and is a serio...

Dec 28th, 2020 - Clostridium difficile infection (CDI) is now the most common cause of healthcare-associated infections, with increasing prevalence, severity, and mortality of nosocomial and community-acquired CDI which makes up approximately one third of all CDI....

Jan 21st, 2019 - Fecal microbiota transplantation (FMT) is becoming part of the treatment algorithms against recurrent Clostridium difficile infection (rCDI) both in adult and pediatric gastroenterology practice. With our increasing recognition of the critical rol...

Sep 3rd, 2018 - The use of faecal microbiota transplant as treatment for recurrent or refractory Clostridium difficile infection and other potential indications: joint British Society of Gastroenterology (BSG) and Healthcare Infection Society (HIS) guidelines.|20...

Aug 31st, 2018 - The aim of this work was to develop a clinical practice guideline for the prevention and treatment of Clostridium difficile infection (CDI) in children and adolescents with cancer and pediatric hematopoietic stem-cell transplantation (HSCT) patients.

Aug 29th, 2018 - Interest in the therapeutic potential of faecal microbiota transplant (FMT) has been increasing globally in recent years, particularly as a result of randomised studies in which it has been used as an intervention. The main focus of these studies ...

Aug 27th, 2018 - Interest in the therapeutic potential of faecal microbiota transplant (FMT) has been increasing globally in recent years, particularly as a result of randomised studies in which it has been used as an intervention. The main focus of these studies.

Feb 12th, 2021 - Background: Proton pump inhibitor (PPI) exposure is associated with Clostridium difficile infection (CDI). The impact of the route of administration is unknown. Patients in the Multiparameter Intelligent Monitoring in Intensive Care II database (M...

Feb 3rd, 2021 - Proton pump inhibitor (PPI) use is extremely common. PPIs have been suggested to affect the gut microbiome, and increase risks of Clostridium difficile infection and small intestinal bacterial overgrowth (SIBO). However, existing data are based on...

Dec 31st, 2020 - Empiric antimicrobial therapy for healthcare-acquired infections often includes vancomycin plus an antipseudomonal beta-lactam (AP-BL). These agents vary in risk for adverse events, including acute kidney injury (AKI) and Clostridium difficile inf...

Dec 30th, 2020 - Infectious diseases are a threat to elderly individuals, whose immune systems weaken with age. Among the various infectious diseases, Clostridium difficile infection is associated with a high rate of mortality in elderly individuals and is a serio...

Dec 28th, 2020 - Clostridium difficile infection (CDI) is now the most common cause of healthcare-associated infections, with increasing prevalence, severity, and mortality of nosocomial and community-acquired CDI which makes up approximately one third of all CDI....

Dec 16th, 2019 - Although fecal microbiota transplantation (FMT) has not yet received approval from the US Food and Drug Administration (FDA), more than 10,000 patients receive FMT in the United States each year to treat Clostridium difficile infection, and hundre...

Jun 3rd, 2019 - Review of Probiotoc Literature Conflicting data exist about probiotics and their effect on CDI prevention. The literature reviewed was selected based on our assessment of its contribution to the topic and its potential utility to clinicians in det.

May 12th, 2019 - Performing fecal microbiota transplantation in medically uncompromised obese individuals did not result in weight loss nor an increase of the gut hormone glucagon-like peptide 1 (GLP-1) at 12 weeks, but it did contribute to a decrease in primary b.

Apr 24th, 2019 - Longer duration of antibiotic prophylaxis after major surgery was associated with higher odds of acute kidney injury (AKI) and higher odds of Clostridium difficile infection, researchers found. There was a duration-dependent relationship between o...

Feb 5th, 2019 - Could fecal microbiota transplantation (FMT), whereby medical-processed stool material from a healthy donor is introduced into the intestine of a patient with obesity, be one of the answers to tackling this disease? That is the belief of several g...